chr9-95485866-G-A
Variant summary
Our verdict is Pathogenic. The variant received 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The ENST00000429896.6(PTCH1):c.-51C>T variant causes a 5 prime UTR premature start codon gain change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
ENST00000429896.6 5_prime_UTR_premature_start_codon_gain
Scores
Clinical Significance
Conservation
Publications
- basal cell nevus syndrome 1Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
- holoprosencephaly 7Inheritance: AD Classification: DEFINITIVE, LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), G2P
- nevoid basal cell carcinoma syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Orphanet
- holoprosencephalyInheritance: AD Classification: LIMITED Submitted by: Illumina
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 14 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: ENST00000429896.6. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| PTCH1 | NM_000264.5 | MANE Select | c.403C>T | p.Arg135* | stop_gained | Exon 3 of 24 | NP_000255.2 | ||
| PTCH1 | NM_001083603.3 | MANE Plus Clinical | c.400C>T | p.Arg134* | stop_gained | Exon 3 of 24 | NP_001077072.1 | ||
| PTCH1 | NM_001083604.3 | c.-51C>T | 5_prime_UTR_premature_start_codon_gain | Exon 3 of 24 | NP_001077073.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| PTCH1 | ENST00000429896.6 | TSL:1 | c.-51C>T | 5_prime_UTR_premature_start_codon_gain | Exon 3 of 24 | ENSP00000414823.2 | |||
| PTCH1 | ENST00000546820.5 | TSL:1 | c.-51C>T | 5_prime_UTR_premature_start_codon_gain | Exon 3 of 7 | ENSP00000448843.1 | |||
| PTCH1 | ENST00000547672.5 | TSL:1 | c.-51C>T | 5_prime_UTR_premature_start_codon_gain | Exon 3 of 7 | ENSP00000447878.1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Gorlin syndrome Pathogenic:1
This sequence change creates a premature translational stop signal (p.Arg135*) in the PTCH1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PTCH1 are known to be pathogenic (PMID: 16301862, 16419085). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with basal cell nevus syndrome (PMID: 8981943, 9415689, 16508594). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 428839). For these reasons, this variant has been classified as Pathogenic.
not provided Pathogenic:1
Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 18502968, 16301862, 16508594, 20690502, 30610186, 29575684, 33825892, 24204797, 33441926, 8981943)
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.R135* pathogenic mutation (also known as c.403C>T), located in coding exon 3 of the PTCH1 gene, results from a C to T substitution at nucleotide position 403. This changes the amino acid from an arginine to a stop codon within coding exon 3. This mutation has previously been identified in an individual with sporadic NBCCS (Wicking C et al. Am J Hum Genet, 1997 Jan;60:21-6). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at